Evidence map›Paper›PMID 40924249›Full record

ArticleAnnals of surgical oncology2025

Clinical Significance of Circulating Tumor Cells in the Portal Vein of Patients with Hepatocellular Carcinoma Undergoing Anatomical Liver Resection.

Daisuke Takei, Tsuyoshi Kobayashi, Michinori Hamaoka, Keiso Matsubara, Ko Oshita, Yosuke Namba, Takeshi Tadokoro, Yuka Tanaka, Shintaro Kuroda, Hideki Ohdan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daisuke TakeiDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Tsuyoshi KobayashiDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. tsukoba@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0001-7364-1798
Michinori HamaokaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Keiso MatsubaraDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Ko OshitaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yosuke NambaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takeshi TadokoroDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yuka TanakaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Shintaro KurodaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Funding

Japan Agency for Medical Research and Development JP24fk0210108Japan Society for the Promotion of Science JP18K08706Japan Society for the Promotion of Science JP20K17654Japan Society for the Promotion of Science JP24K02522
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) frequently invades the portal vein, leading to early recurrence and a poor prognosis. However, the mechanisms underlying this invasion remain unclear. In this study, we aimed to detect portal vein circulating tumor cells (CTCs) using a Glypican-3-positive detection method and evaluate their prognostic significance.

methodsThis prospective study included 146 patients with HCC who underwent open anatomical hepatectomy. Blood samples from the peripheral, portal, and hepatic veins were collected intraoperatively, and CTCs were detected using magnetic enrichment and flow cytometry. Programmed cell death ligand 1 (PD-L1) expression in portal CTCs was evaluated in 40 patients.

resultsPortal vein CTCs were detected in 45.8% of cases, more frequently than hepatic vein CTCs (p = 0.031). Portal vein CTC positivity correlated with microscopic portal vein invasion (p < 0.001), poorer disease-free survival (p = 0.014), and overall survival (p = 0.001). PD-L1-positive portal vein CTCs were observed in 13 of 40 cases (32.5%) and were significantly associated with poorer prognosis (p = 0.001).

conclusionsPortal vein CTCs are significant predictors of portal vein invasion, recurrence, and survival in HCC. PD-L1-positive portal vein CTCs may contribute to immune evasion and tumor progression. These findings suggest that portal vein CTCs are valuable prognostic biomarkers and potential therapeutic targets.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularHepatectomyLiver NeoplasmsNeoplasm Recurrence, LocalNeoplastic Cells, CirculatingPortal VeinAdultAgedB7-H1 AntigenClinical RelevanceFemaleFollow-Up StudiesGlypicansHumansMaleB7-H1 AntigenBiomarkers, TumorCD274 protein, humanGlypicansCirculating tumor cellsGlypican-3Hepatocellular carcinomaPD-L1Portal vein invasion

Identifiers

PMID40924249
PMCPMC12589225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.